94 related articles for article (PubMed ID: 3791954)
1. Pyrimidinones: inducers of NK cell activity and antitumor immunity.
Lotzová E; Savary CA
Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):185-91. PubMed ID: 3791954
[TBL] [Abstract][Full Text] [Related]
2. Induction of tumor immunity and natural killer cell cytotoxicity in mice by 5-halo-6-phenyl pyrimidinone.
Lotzová E; Savary CA; Pollack S; Hanna N
Cancer Res; 1986 Oct; 46(10):5004-8. PubMed ID: 3756861
[TBL] [Abstract][Full Text] [Related]
3. Studies on the antitumor activities of pyrimidinone-interferon inducers. Part 2. Potentiation of antitumor resistance mechanisms.
Milas L; Hunter N; Ito H; Lotzová E; Stringfellow DA
Clin Exp Metastasis; 1983; 1(3):213-22. PubMed ID: 6336272
[TBL] [Abstract][Full Text] [Related]
4. Studies on the antitumor activities of pyrimidinone-interferon inducers. I. Effect against artificial and spontaneous lung metastases of murine tumors.
Milas L; Hersh EM; Stringfellow DA; Hunter N
J Natl Cancer Inst; 1982 Jan; 68(1):139-45. PubMed ID: 6172625
[TBL] [Abstract][Full Text] [Related]
5. 5-halo-6-phenyl pyrimidinones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells.
Lotzová E; Savary CA; Stringfellow DA
J Immunol; 1983 Feb; 130(2):965-9. PubMed ID: 6848603
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and morphologic profile of endogenous and pyrimidinone-activated murine NK cells.
Lotzová E; Savary CA; Lowlachi M; Murasko DM
J Immunol; 1986 Jan; 136(2):732-40. PubMed ID: 2416824
[TBL] [Abstract][Full Text] [Related]
7. 5-Halo-6-phenyl pyrimidinones and 8-substituted guanosines: biological response modifiers with similar effects on B cells.
Wicker LS; Ashton WT; Boltz RC; Meurer LC; Miller BJ; Nichols EA; Sigal NH; Tolman RL; Peterson LB
Cell Immunol; 1988 Mar; 112(1):156-65. PubMed ID: 3257907
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.
Fujioka T; Ishikura K; Hasegawa M; Ogyu K; Matsushita Y; Sato M; Sato F; Aoki H; Kubo T
Cancer Chemother Pharmacol; 1995; 36(1):7-12. PubMed ID: 7536641
[TBL] [Abstract][Full Text] [Related]
9. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo.
Richard KA; Mortensen RF; Tracey DE
J Biol Response Mod; 1987 Dec; 6(6):647-63. PubMed ID: 2453616
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells.
Divino CM; Chen SH; Yang W; Thung S; Brower ST; Woo SL
Breast Cancer Res Treat; 2000 Mar; 60(2):129-34. PubMed ID: 10845275
[TBL] [Abstract][Full Text] [Related]
11. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy.
Stolfi RL; Martin DS; Fugmann RA
Cancer Chemother Rep; 1971 Jun; 55(3):239-51. PubMed ID: 4329953
[No Abstract] [Full Text] [Related]
13. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.
Lala PK; Parhar RS; Singh P
Cell Immunol; 1986 Apr; 99(1):108-18. PubMed ID: 2944621
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of effector cell functions in natural killer cell activity (NK) and antibody-dependent cellular cytotoxicity (ADCC) in mice by normal and cancer sera.
Nair PN; Fernandes G; Onoe K; Day NK; Good RA
Int J Cancer; 1980 May; 25(5):667-77. PubMed ID: 7372374
[No Abstract] [Full Text] [Related]
15. Decreased natural cytotoxicity in mice with high incidence of mammary adenocarcinoma.
Ames IH; Garcia AM; John PA; Litty CA; Farrell MA; Tomar RH
Clin Immunol Immunopathol; 1986 Feb; 38(2):265-73. PubMed ID: 3940744
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma.
Matsushita K; Kuramitsu Y; Ohiro Y; Obara M; Kobayashi M; Li YQ; Hosokawa M
Anticancer Drugs; 1998 Apr; 9(4):343-50. PubMed ID: 9635925
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo.
Pavlak M; Stojković R; Radacić-Aumiler M; Kasnar-Samprec J; Jercić J; Vlahović K; Zinić B; Radacić M
J Cancer Res Clin Oncol; 2005 Dec; 131(12):829-36. PubMed ID: 16158306
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
19. Site-specific antitumour effects of 2 pyrimidinone compounds in rats.
Eggermont AM; Marquet RL; De Bruin RW; Weimar W; Jeekel J
Br J Cancer; 1986 Aug; 54(2):337-9. PubMed ID: 3741769
[No Abstract] [Full Text] [Related]
20. Effects of 5-halopyrimidinones with antiviral and antineoplastic activity on murine cytochrome P-450.
Crowe D; Nerland DE; Stringfellow DA; Sonnenfeld G
J Biol Response Mod; 1984; 3(1):15-8. PubMed ID: 6707696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
